Geoffrey Ku, ASCO GI 2021: The Addition of Durvalumab to Chemoradiation for Esophageal Adenocarcinoma

We were delighted to talk to Geoffrey Ku (Memorial Sloan Kettering Cancer Center, New York, US) about the addition of durvalumab to induction FOLFOX and PET-directed chemoradiation for esophageal adenocarcinoma (Clinical Trial Identifier: NCT02962063). The abstract ‘Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma’ (ABSTRACT NUMBER: 226) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.

Questions

1. Why is there a need for multimodal treatment strategies for patients with esophageal adenocarcinoma? (0:16)
2. What is the rationale for the addition of durvalumab to the treatment regimen of induction FOLFOX and PET-directed chemoradiation in the treatment of esophageal adenocarcinoma? (1:06)
3. Could you tell us about your recent study and its findings? (2:23)
4. What will be the impact of these findings on clinical practice and what further studies are planned? (3:37)

Disclosures: Geoffrey Ku reports Research Support from Arog, AstraZeneca, BMS, Daiichi Sankyo, Merck, Oncolys, Pieris and Zymeworks, and Consulting for Apexigen, BMS, IMAB and Pieris.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of ASCO GI 2021 (Virtual).